The National Institutes of Health’s Acute Respiratory Distress Syndrome (ARDS), Pneumonia, and Sepsis Phenotyping Consortium, supported by Intermountain Health, aims to leverage artificial intelligence (AI) technologies to gain a deeper understanding of critical illness syndromes. With a grant of $51.6 million from NIH, researchers from 22 hospitals in the U.S. will work together to develop more precise treatments for ARDS, sepsis, and pneumonia. The consortium plans to enroll 5,000 patients within the next five years and will explore subtypes of these syndromes to identify targeted treatment approaches.
To achieve this goal, researchers will conduct blood and genetic tests and closely monitor patients’ progress and outcomes. Through the use of AI and advanced analytics, they aim to identify patient types and actionable targets within each group for conducting future clinical trials. Leading institutions such as Intermountain Health, Vanderbilt University Medical Center, University of California San Francisco, University of Colorado, University of Michigan, and University of Pennsylvania have been named as key sites for this study.
ARDS and sepsis, often induced by pneumonia, have high mortality rates of up to 50% and are known to lack effective therapies. Tragically, during the COVID-19 pandemic, many critically ill patients succumbed to these conditions. Sepsis alone affects approximately 1.7 million adults in the U.S. annually, and it presents across various population groups, from neonates to adult trauma patients.
The federal government is also investing in predictive algorithms, including the analysis of biometric data from commercial wearables to predict disease outcomes. Dr. Samuel Brown, Intermountain Health vice president for research, emphasized the importance of precision medicine for critically-ill patients, underscoring the need for accurate and targeted approaches to their care.
The collaboration between the National Institutes of Health, Intermountain Health, and leading institutions across the U.S. aims to revolutionize the treatment approach for critical illnesses like ARDS, sepsis, and pneumonia. By harnessing the power of AI and advanced analytics, researchers hope to uncover patient subtypes and precise treatment strategies for these syndromes. This holistic and tailored approach has the potential to save lives and significantly improve outcomes for critically ill patients.
The whytry.ai article you just read is a brief synopsis; the original article can be found here: Read the Full Article…
